U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07875907) titled 'Repurposing Mefloquine for Pancreatic Cancer Treatment' on Oct. 08.
Brief Summary: Pancreatic cancer (specifically pancreatic ductal adenocarcinoma, PDAC) is a very aggressive disease that is often diagnosed too late for surgery, and the medicines currently available, mainly two chemotherapy combinations called modified FOLFIRINOX (mFFX) and gemcitabine + nab-paclitaxel (GnP), can extend life but rarely cure patients.
This study examines mefloquine, a well-studied antimalarial drug, as a new way to attack pancreatic cancer. Laboratory work has shown that mefloquine can block an enzyme (TYMS) that cancer cells need to make DNA, and ...